| Essential Hypertension

Azor vs Edarbyclor

Side-by-side clinical, coverage, and cost comparison for essential hypertension.
Deep comparison between: Azor vs Edarbyclor with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsEdarbyclor has a higher rate of injection site reactions vs Azor based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Edarbyclor but not Azor, including UnitedHealthcare
Sign up to reveal the full AI analysis
Azor
Edarbyclor
At A Glance
Oral
Once daily
CCB / ARB combination
Oral
Once daily
ARB / thiazide-like diuretic
Indications
  • Essential Hypertension
  • Essential Hypertension
Dosing
Essential Hypertension Starting dose 5/20 mg once daily; may be increased after 1-2 weeks to a maximum of 10/40 mg once daily as needed to control blood pressure.
Essential Hypertension Starting dose 40/12.5 mg orally once daily; may increase to 40/25 mg after 2 to 4 weeks as needed to achieve blood pressure goals; maximum dose 40/25 mg.
Contraindications
  • Co-administration of aliskiren in patients with diabetes
  • Anuria
  • Coadministration of aliskiren-containing products in patients with diabetes
Adverse Reactions
Most common (>=3%) Edema
Postmarketing (amlodipine) Gynecomastia, jaundice, hepatic enzyme elevations, extrapyramidal disorder
Postmarketing (olmesartan medoxomil) Asthenia, angioedema, anaphylactic reactions, peripheral edema, vomiting, diarrhea, sprue-like enteropathy, hyperkalemia, rhabdomyolysis, acute renal failure, alopecia, pruritus, urticaria
Most common (>=2%) Dizziness, fatigue
Serious Hypotension, syncope, increased serum creatinine, hypokalemia, hyperuricemia
Postmarketing Loss of consciousness, pruritus, angioedema
Pharmacology
Azor combines amlodipine, a dihydropyridine calcium channel blocker that inhibits transmembrane calcium ion influx into vascular smooth muscle and cardiac muscle to reduce peripheral vascular resistance, with olmesartan medoxomil, an angiotensin II receptor blocker that selectively blocks AT1 receptors in vascular smooth muscle to oppose the vasoconstrictor effects of angiotensin II.
Azilsartan is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors to inhibit vasoconstriction and aldosterone secretion; chlorthalidone is a thiazide-like diuretic that inhibits NaCl reabsorption in the distal renal tubule, reducing extracellular fluid volume and blood pressure via complementary mechanisms.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Azor
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
View full coverage details ›
Edarbyclor
  • Covered on 5 commercial plans
  • PA (6/12) · Step Therapy (6/12) · Qty limit (12/12)
View full coverage details ›
UnitedHealthcare
Azor
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
View full coverage details ›
Edarbyclor
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
View full coverage details ›
Humana
Azor
  • Covered on 0 commercial plans
  • PA (2/3) · Step Therapy (2/3) · Qty limit (1/3)
View full coverage details ›
Edarbyclor
  • Covered on 0 commercial plans
  • PA (0/3) · Step Therapy (2/3) · Qty limit (2/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Azor.
No savings programs available for Edarbyclor.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
AzorView full Azor profile
EdarbyclorView full Edarbyclor profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.